At the Herbert Irving Comprehensive Cancer Center at Columbia University and NewYork-Presbyterian Hospital, we believe that our discoveries here will end cancer everywhere.
Working together, we empower innovation and discovery in prevention, research and clinical care to reduce the burden of cancer for our patients, our community, and the world.
Dr. Lamanna Discusses the MURANO Trial in CLL
January 2nd 2019Nicole Lamanna, MD, associate professor of medicine, Hematologic Malignancies Section, Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, discusses the MURANO trial in patients with chronic lymphocytic leukemia.
Dr. Kalinsky on CNS Involvement in HER2+ Breast Cancer
September 20th 2018Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses central nervous system involvement in HER2-positive breast cancer.
Dr. Kalinsky Discusses the Evolution of HER2+ Breast Cancer
September 5th 2018Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the evolution of treatment for patients with HER2-positive metastatic breast cancer.
Dr. Kalinsky on Neratinib and Tucatinib in HER2+ Metastatic Breast Cancer
August 8th 2018Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the potential of neratinib (Nerlynx) and tucatinib in HER2-positive metastatic breast cancer.
Dr. Drake on the Role of Cytoreductive Nephrectomy in RCC
August 7th 2018Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma.
Dr. Drake Discusses the Results of the CARMENA Study in RCC
August 2nd 2018Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the results of the CARMENA study in patients with metastatic renal cell carcinoma.
Dr. Drake Discusses Immunotherapy Agents in Bladder Cancer
April 28th 2017Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses immunotherapy agents in bladder cancer.
Dr. Drake on Immunotherapy Side Effects in Genitourinary Cancers
March 4th 2017Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the side effects associated with immunotherapy in genitourinary cancers.
Dr. Drake on Promise of Immunotherapy Combinations in Genitourinary Cancers
February 23rd 2017Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the potential of combinations between immunotherapy and conventional therapies in genitourinary cancers.
Dr. Kalinsky on Ruxolitinib Plus Trastuzumab in HER2-Positive Breast Cancer
January 11th 2017Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses a phase I study of ruxolitinib (Jakafi) in combination with trastuzumab (Herceptin) in metastatic HER2-positive breast cancer.
Dr. Richard Carvajal on Selumetinib/ Dacarbazine in Uveal Melanoma
March 10th 2016Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses the phase III SUMIT trial, a randomized, placebo-controlled, double-blind trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma.
Expert Sees Major Genomic Knowledge Gaps in Cervical Cancer
Today, in his laboratory at Columbia University, Murty Vundavalli, PhD continues working to understand the genetic and epigenetic aspects of cervical cancer in an attempt to elucidate prognostic markers of response to treatment.
Dr. O'Connor on Targeting CD30 in DLBCL
September 10th 2015Owen A. O'Connor, MD, PhD, professor of Medicine and Experiment Therapies, co-program director, Lymphoid Development and Malignancy Program, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses targeting CD30 expression in patients with diffuse large B-cell lymphoma.
Dr. Gary Schwartz on the Survival Benefit of Eribulin In Sarcoma
June 19th 2015Gary Schwartz, MD, a medical oncologist and chief of the Hematology and Oncology Division at Columbia University Medical Center, discusses a randomized phase III trial investigating eribulin (Halaven) versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcomas.
Dr. Jurcic on Lintuzumab and Low-Dose Cytarabine for AML
June 11th 2015Joseph Jurcic, MD, professor of Clinical Medicine, director of the Hematologic Malignancies Section of the Hematology/Oncology Division, Columbia University Medical Center, discusses a phase I trial of lintuzumab and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).
Dr. Lamanna on Incorporating Novel and Traditional Therapies in CLL
May 15th 2015Nicole Lamanna, MD, Associate Professor of Clinical Medicine, Columbia University Medical Center, discusses incorporating novel therapies into the standard treatment paradigm for patients with chronic lymphocytic leukemia (CLL).